Omeros (OMER) Initiates Phase 3 for OMS721 Following FDA Meeting

March 8, 2016 7:03 AM

Omeros Corporation (NASDAQ: OMER) initiated its Phase 3 OMS721 program for the treatment of atypical hemolytic uremic syndrome (aHUS) after ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found